Cited by 33RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryVirus-based gene therapy research

Receptor-mediated gene transfer vectors: progress towards genetic pharmaceuticals

Molas, M., Gomez-Valades, A., Vidal-Alabro, A., Miguel-Turu, M., Bermudez, J., Bartrons, R., Perales, J.·2003·Current Gene Therapy

Abstract

Although specific delivery to tissues and unique cell types in vivo has been demonstrated for many non-viral vectors, current methods are still inadequate for human applications, mainly because of limitations on their efficiencies. All the steps required for an efficient receptor-mediated gene transfer process may in principle be exploited to enhance targeted gene delivery. These steps are: DNA/vector binding, internalization, subcellular trafficking, vesicular escape, nuclear import, and unpacking either for transcription or other functions (i.e., antisense, RNA interference, etc.). The large variety of vector designs that are currently available, usually aimed at improving the efficiency of these steps, has complicated the evaluation of data obtained from specific derivatives of such vectors. The importance of the structure of the final vector and the consequences of design decisions at specific steps on the overall efficiency of the vector will be discussed in detail. We emphasize in this review that stability in serum and thus, proper bioavailability of vectors to their specific receptors may be the single greatest limiting factor on the overall gene transfer efficiency in vivo. We discuss current approaches to overcome the intrinsic instability of synthetic vectors in the blood. In this regard, a summary of the structural features of the vectors obtained from current protocols will be presented and their functional characteristics evaluated. Dissecting information on molecular conjugates obtained by such methodologies, when carefully evaluated, should provide important guidelines for the creation of effective, targeted and safe DNA therapeutics.

Integrity signals

Registry

Crossref · 10.2174/1566523034578195

Cites

151 of 151 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many types of ligands, such as folate, transferrin, antibody and aptamer, can be incorporated into non-viral vectors to boost cellular uptake via receptor-mediated endocytosis.

    “Meanwhile, many types of ligands, such as folate, transferrin, antibody and aptamer, etc., can also be incorporated into the non-viral vectors to boost cellular uptake via receptor-mediated endocytosis [171–173].”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Molas, M., Gomez-Valades, A., Vidal-Alabro, A., Miguel-Turu, M., Bermudez, J., Bartrons, R., & Perales, J.
Affiliations
Universitat de Barcelona (ES)
Venue
Current Gene Therapy
Published
2003-10-01
Volume
3
Issue
5
Pages
468-485
ISSN
1566-5232 (ISSN-L)
OpenAlex
W2009253092
Cited by
33
References
151
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2015: 2
FWCI
0.69
Type
journal article
Language
en
Open access
closed
Locations
  • Current Gene Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
receptor-mediated gene transfer, non-viral vectors, targeted gene delivery, serum stability, DNA internalization, intracellular trafficking, nuclear import, antisense therapeutics, RNA interference, vector design
MeSH terms
Genetic Vectors, Drug Design, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review